ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BMK Benchmark Holdings Plc

43.50
0.25 (0.58%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Benchmark Holdings Plc LSE:BMK London Ordinary Share GB00BGHPT808 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.25 0.58% 43.50 43.00 43.50 42.90 42.40 42.90 334,274 16:35:10
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 169.74M -23.15M -0.0313 -13.71 317.18M
Benchmark Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker BMK. The last closing price for Benchmark was 43.25p. Over the last year, Benchmark shares have traded in a share price range of 33.80p to 48.00p.

Benchmark currently has 739,352,390 shares in issue. The market capitalisation of Benchmark is £317.18 million. Benchmark has a price to earnings ratio (PE ratio) of -13.71.

Benchmark Share Discussion Threads

Showing 526 to 549 of 1100 messages
Chat Pages: Latest  32  31  30  29  28  27  26  25  24  23  22  21  Older
DateSubjectAuthorDiscuss
04/11/2017
12:03
Yep, but that's the way to value a company like this, surely. It's not the sole pioneer in its field and, unlike a biotech, the end markets here are generally much smaller

Might be missing something obvious ?

dan_the_epic
04/11/2017
11:52
You mean the martket cap vs profit? Yes I think that's why I liken it to a biotech.

In 2013 it listed at 64p but the share price opened at 75p and was £1.45 within days.

Like I said not necessarily one to trade but stick it away I think it'll move nicely

john09
04/11/2017
11:49
Valuation here is still mental though
dan_the_epic
04/11/2017
11:45
Yes I've not bought it to trade but looks like it's bottomed out. Reminds me a bit of a biotech company with plenty of R&D and future promise. Actually I think it'll get taken out judging by the pipeline of products at various stages of development. I think it's a buy and hold til it's taken private.
john09
04/11/2017
09:19
Think where we are now is a decent entry point bought a good few for my SIPP a few weeks ago what will a penny or two matter in the long term.
we have had an update on the current trading which will be in line the below taken from the update on 08.09.17, Looks good to me .

Overall performance across the Group has been good, with strong growth in sales in the Breeding and Genetics Division, and improved market conditions for the Advanced Animal Nutrition Division in the second half.

wskill
03/11/2017
14:32
Looks like my order filled . I'm in
john09
03/11/2017
10:11
I'm looking to buy some of these.

- What are people's entry points out of interest?
- What do you see as the potential share price catalysts in 2018?

john09
30/10/2017
12:16
SCSW very bullish on this
nw99
30/10/2017
09:10
Story in the independent today:
bikwik
30/10/2017
07:19
Decent RNS this morning coupled with a positive write up in this weekend's SCSW might see a bit of upwards movement today.

Dibbs

dibbs
17/10/2017
09:25
Advfn missing the RNS this morning:

RNS Number : 7497T
Benchmark Holdings PLC
17 October 2017

Benchmark Holdings plc
("Benchmark" or the "Company")

New Vaccine Facility Delivers first Commercial Scale Production

Benchmark today announces that operations commenced at its state-of-the-art vaccine antigen production facility in Braintree, UK on 29 September 2017. The £17m Biotechnology Building has processed its first commercial-scale batch of antigen, which will be used in a number of new aquaculture vaccines in Benchmark's product pipeline.

Work on the final validation of the facility to ensure compliance with EU Good Manufacturing Practices (GMP) is underway and once fully licensed the increased capacity will allow the Company to significantly expand the number and range of vaccines it produces.

The 2,500-square-metre facility is set to be one of the most capable EU GMP antigen production facilities in Europe.

Malcolm Pye, Benchmark CEO, commented;

"This is a significant milestone for Benchmark. The new facility provides the foundation for the large-scale antigen manufacture and testing of our new pipeline products, and represents the engine room through which our ground-breaking products can be delivered on a large commercial scale."

phowdo
17/10/2017
09:10
17TH OCTOBER 2017
Benchmark today announces that operations commenced at its state-of-the-art vaccine antigen production facility in Braintree, UK on 29 September 2017.

martincc
17/10/2017
08:44
Looks like someone is picking up a bit of stock again today after a few quiet days. Dibbs
dibbs
11/10/2017
20:54
Slightly old news but worth a read.



Dibbs

dibbs
11/10/2017
13:04
last MM at 45p, then its 47 to buy
albanyvillas
11/10/2017
10:18
It would appear that there is a genuine lice problem in salmon farming which is hurting yields, and old treatments have ceased to work effectively. the Firm to come up with the next groundbreaking treatment which works will make a ton of money here. Can't guarantee it'll be BMK, but they have been developing a new product here, and they definitely have a shot. Probably no coincidence that Ferd is a Norwegian Company and hence will have good knowledge of salmon farming, given that Norway leads the world in this area. Exciting stuff!
ilovefrogs
11/10/2017
09:30
Bid from Ferd at 90p do me. Mighty fine
larva
11/10/2017
09:29
60p next then 80p
larva
11/10/2017
08:28
I suppose it could have been the seller re those two lots which almost totalled 5 million.
bikwik
11/10/2017
08:26
Posted this yesterday on my thread:

Well we now know who bought 5 million BMK shares today.....FERD AS....

From Linked in

Ferd is a family-owned Norwegian industrial and financial group that is an active and long-term owner of strong companies with international potential and carries out financial activities through investments in a broad range of asset classes. In addition to the group’s purely commercial activities, Ferd has an extensive involvement in social entrepreneurship.

Ferd is made up of six business areas; Ferd Capital, Ferd Invest, Ferd Hedge Funds, Ferd Special Investments, Ferd Real Estate and Ferd Social Entrepreneurs.

Don't know about the other two lots of 4,330,000 and 669,224 shares, maybe it was them as well. They now have 17.6% quite a chunk!

Watch this space!

bikwik
10/10/2017
19:21
Genus cud bid
opodio
10/10/2017
16:19
yeh, bought back in yesterday and today - hopefully will go on a decent run and the new lice treatment trials will start before the end of the year.
cumbrian2
10/10/2017
16:13
Looks like the or a seller clearer out today Numis giving them a push, about time.....
exbroker
03/10/2017
08:24
SORRY wrong share
nimrod22
Chat Pages: Latest  32  31  30  29  28  27  26  25  24  23  22  21  Older

Your Recent History

Delayed Upgrade Clock